{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T18:52:12Z","timestamp":1773168732842,"version":"3.50.1"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014471","name":"Mundipharma Research Limited","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec><jats:title>Introduction:<\/jats:title><jats:p> In recognition of the value of long-term real-world data, a postauthorization safety study of the inhaled corticosteroid (ICS) fluticasone propionate and long-acting \u03b2<jats:sub>2<\/jats:sub>-agonist (LABA) formoterol fumarate (fluticasone\/formoterol; Flutiform<jats:sup>\u00ae<\/jats:sup>) was conducted. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> This was a 12-month observational study of outpatients with asthma aged \u2a7e 12 years in eight European countries. Patients were prescribed fluticasone\/formoterol according to the licensed indication, and independently of their subsequent enrolment in the study. They were then treated according to local standard practice. The study objectives were to evaluate the safety and effectiveness of fluticasone\/formoterol under real-world conditions. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> The safety population for this study comprised 2539 patients (mean age 47.7 years; 94.3% aged \u2a7e 18 years; 63.4% female). Most patients (1538\/2539, 60.6%) had switched to fluticasone\/formoterol from another ICS\/LABA, primarily due to lack of efficacy (1150\/2539, 45.3%). Three quarters (77.4%) of patients were treated for 12 months, and 80.6% continued fluticasone\/formoterol treatment after the study. Adverse events (AEs) occurred in 60.0% patients, and 10.2% had AEs considered possibly related to fluticasone\/formoterol [most commonly asthma exacerbation (2.0% patients), dysphonia (1.8%) and cough (1.1%)]. Thirty-six severe AEs, but no serious AEs, were considered possibly related to fluticasone\/formoterol. The proportion of patients with controlled asthma (based on Asthma Control Test score \u2a7e 20) increased from 29.4% at baseline to 67.4% at study end (last observation carried forward). The proportion of patients experiencing at least one severe exacerbation decreased from 35.8% in the year prior to enrolment to 9.8% during the study. Improvements from baseline to study end were also observed in Asthma Quality of Life scores and physician\/patient reports of satisfaction with treatment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> In this real-world postauthorization safety study, fluticasone\/formoterol demonstrated a safety profile consistent with that seen in controlled clinical trials, with effectiveness in improving asthma control. <\/jats:p><\/jats:sec>","DOI":"10.1177\/1753466618796987","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T10:44:08Z","timestamp":1537440248000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Non-interventional study of the safety and effectiveness of fluticasone propionate\/formoterol fumarate in real-world asthma management"],"prefix":"10.1177","volume":"12","author":[{"given":"Vibeke","family":"Backer","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Ellery","sequence":"additional","affiliation":[{"name":"Cape Cornwall Surgery, Penzance, Cornwall, UK St. Just"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Borzova","sequence":"additional","affiliation":[{"name":"FELICEM, s.r.o., Michalovce, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lane","sequence":"additional","affiliation":[{"name":"Professorial Respiratory Centre, Tallaght Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Kleiberova","sequence":"additional","affiliation":[{"name":"ALERGO Kleiberova, s.r.o., Rychnov nad Kneznou, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"Kvartersakuten Morby Centrum, Danderyd, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeusz","family":"Tomala","sequence":"additional","affiliation":[{"name":"Svelvik legesenter, Svelvik, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Basset-Stheme","sequence":"additional","affiliation":[{"name":"Allergology Practice, Valence, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Bennett","sequence":"additional","affiliation":[{"name":"Mundipharma Research Limited, Cambridge Science Park, Milton Rd, Cambridge, CB4 0GW UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Lindner","sequence":"additional","affiliation":[{"name":"Mundipharma Research GmbH and Co. KG, Limburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Meiners","sequence":"additional","affiliation":[{"name":"Mundipharma Research GmbH and Co. KG, Limburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Overend","sequence":"additional","affiliation":[{"name":"Mundipharma Research Limited, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"bibr1-1753466618796987","unstructured":"European Medicines Agency Decision. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Flutiform_29\/WC500125700.pdf (2012, accessed 10 April 2018)."},{"key":"bibr2-1753466618796987","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2012.719253"},{"key":"bibr3-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-012-0058-0"},{"key":"bibr4-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-11-28"},{"key":"bibr5-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.11.011"},{"key":"bibr6-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.10.025"},{"key":"bibr7-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-12-67"},{"key":"bibr8-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.772506"},{"key":"bibr9-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2012.0977"},{"key":"bibr10-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080306"},{"key":"bibr11-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00283202"},{"key":"bibr12-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.5.8630590"},{"key":"bibr13-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92996-3"},{"key":"bibr14-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.122635"},{"issue":"4","key":"bibr15-1753466618796987","first-page":"CD005533","volume":"2010","author":"Ducharme FM","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr16-1753466618796987","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2003.tb05167.x"},{"issue":"5","key":"bibr17-1753466618796987","first-page":"CD005535","volume":"2010","author":"Ducharme FM","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"bibr18-1753466618796987","first-page":"526","volume":"101","author":"Naedele-Risha R","year":"2001","journal-title":"J Am Osteopath Assoc"},{"key":"bibr19-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.06.034"},{"key":"bibr20-1753466618796987","unstructured":"Global initiative for asthma. Global strategy for asthma management and prevention, 2017, http:\/\/www.ginasthma.org (accessed 17 May 2017)."},{"key":"bibr21-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201309-298RM"},{"key":"bibr22-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.015414"},{"key":"bibr23-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201309-300RM"},{"key":"bibr24-1753466618796987","unstructured":"Napp Pharmaceuticals Ltd. Flutiform summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/4277\/smpc (accessed 10 April 2018)."},{"key":"bibr25-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4118"},{"key":"bibr26-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205259"},{"key":"bibr27-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.02.006"},{"key":"bibr28-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.08.017"},{"key":"bibr29-1753466618796987","unstructured":"GlaxoSmithKline. Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care. http:\/\/www.gsk.com\/en-gb\/media\/press-releases\/relvar-ellipta-significantly-improved-asthma-control-in-salford-lung-study-patients-compared-with-their-usual-care\/ (2017, accessed 17 May 2017)."},{"key":"bibr30-1753466618796987","first-page":"OA3193","volume":"50","author":"Leather D","year":"2017","journal-title":"Eur Respir J"},{"key":"bibr31-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2015.1255"},{"key":"bibr32-1753466618796987","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1203730"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466618796987","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753466618796987","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466618796987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:34:50Z","timestamp":1740875690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753466618796987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":32,"alternative-id":["10.1177\/1753466618796987"],"URL":"https:\/\/doi.org\/10.1177\/1753466618796987","relation":{},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"article-number":"1753466618796987"}}